QPPV.COM KNOWLEDGE ASSESSMENT

Elranatamab: Classification, Mechanism, Clinical Use and Pharmacovigilance

Test your understanding of the concepts covered by Elranatamab: Classification, Mechanism, Clinical Use and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient develops fever, transient hypotension and mild hypoxia several hours after the first step-up dose. Which additional information would be most important for evaluating possible CRS?

The patient’s preferred pharmacy and insurance status Dose level and sequence, symptom onset time, maximum temperature, haemodynamics, oxygen requirement and treatment administered Only the patient’s tumour response six months later Only whether the patient had ever received an antibiotic

Question 2 of 10 Which combination of factors best explains the longitudinal infection risk associated with elranatamab?

Only transient fever after the first dose Heavily pretreated myeloma, marrow suppression, corticosteroid exposure, plasma-cell depletion and hypogammaglobulinaemia BCMA expression on malignant cells without any effect on normal plasma cells Improved tumour response and recovery of immune function

Question 3 of 10 Why can treatment with elranatamab contribute to hypogammaglobulinaemia?

BCMA is expressed only on malignant cells, so hypogammaglobulinaemia is unrelated to the drug’s target CD3 binding permanently disables all T-cell antibody production BCMA-related biology is also relevant to normal plasma cells, so their depletion can reduce normal immunoglobulin production Elranatamab directly inhibits hepatic immunoglobulin synthesis

Question 4 of 10 Which statement best describes the relationship between CRS and ICANS during elranatamab treatment?

ICANS can occur only if CRS has already resolved ICANS and CRS are unrelated to immune activation and should be assessed independently of treatment timing Neurological toxicity may occur with, after or independently of CRS, so timing should be documented rather than assumed ICANS is simply a more severe form of neutropenia

Question 5 of 10 Which documentation approach best supports assessment of possible ICANS in an elranatamab case?

Record only the term “confusion” without further clinical detail Record structured neurological findings, baseline neurological status, timing and relevant competing diagnoses Record only the patient’s immunoglobulin concentration Assume every neurological symptom is ICANS if it follows an injection

Question 6 of 10 An organisation has a list of labelled adverse reactions but cannot determine whether reported fevers occurred after step-up dosing, during neutropenia or with positive cultures. What is the principal governance concern?

The organisation has sufficient information because adverse-event lists do not require clinical context The organisation may be unable to distinguish expected pharmacodynamic toxicity from clinically important infection or other toxicity The organisation should remove fever from its safety database The organisation should classify all such cases as medication errors

Question 7 of 10 What is the principal pharmacovigilance rationale for step-up dosing with elranatamab?

It eliminates the possibility of CRS after the first dose It reduces the size of the initial immune perturbation and permits early toxicity to be recognised before full-dose exposure It ensures that all later doses are pharmacologically inactive It is used primarily to improve renal elimination of the antibody

Question 8 of 10 Which intervention would best support safe operational implementation across inpatient, outpatient and emergency-care settings?

Rely on verbal handover without maintaining a dose history Maintain a treatment record linking each dose to sequence position, premedication, observation period and toxicity outcome Allow each care setting to reconstruct the schedule independently Record only whether the patient received the product during the current month

Question 9 of 10 A patient develops neutropenia during elranatamab treatment. Which approach is most appropriate for attribution?

Attribute it automatically to elranatamab because it occurred after treatment began Use the laboratory trajectory and assess baseline counts, nadir, recovery, disease status, prior therapy, infection and marrow-active concomitant medicines Disregard it because cytopenias are expected in multiple myeloma Attribute it exclusively to infection without evaluating other causes

Question 10 of 10 Why are medication errors involving the step-up schedule independently important in pharmacovigilance?

They have no safety relevance unless an adverse event is reported They may alter the expected exposure-toxicity relationship and can complicate interpretation of subsequent CRS or other immune toxicity They are relevant only to product quality investigations They reduce exposure and therefore cannot increase risk

Elranatamab: Classification, Mechanism, Clinical Use and Pharmacovigilance

Cookie Settings